The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
Cardiovascular Complications of Cancer Therapy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Chronic Health Conditions in Adult Survivors of Childhood Cancer
Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa060185 · Cited by 3,597
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181940 · Cited by 1,853
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071028 · Cited by 1,719
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., & White, H. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.011 · Cited by 1,618
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Antman, E. M., Hand, M., Armstrong, P. W., Bates, E. R., Green, L. A., Halasyamani, L. K., Hochman, J. S., Krumholz, H. M., Lamas, G. A., Mullany, C. J., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.188209 · Cited by 1,562
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.013 · Cited by 1,510
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6723 · Cited by 1,032
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,026
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 990
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Adjuvant Docetaxel for Node-Positive Breast Cancer
Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J.-P., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043681 · Cited by 954
Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H.-P., Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 938
Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Antman, E. M., Armstrong, P. W., Green, L. A., Halasyamani, L. K., Hochman, J. S., Krumholz, H. M., Lamas, G. A., Smith, S. C., Hand, M., Bates, E. R., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.001 · Cited by 892
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826
Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 808
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801
Kantarjian, H. M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F.-E., O'Brien, S. G., Litzow, M., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080689 · Cited by 746
Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention
Pai, V. B., & Nahata, M. C. (2000) · Drug Safety · doi:10.2165/00002018-200022040-00002 · Cited by 729
Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Walko, C. M., & Lindley, C. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.01.005 · Cited by 659
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1611 · Cited by 566
Perez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5467 · Cited by 538
Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide Angiocardiography
Alexander, J., Dainiak, N., Berger, H. J., Goldman, L., Johnstone, D., Reduto, L., Duffy, T., Schwartz, P., Gottschalk, A., Zaret, B. L., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197902083000603 · Cited by 535
UNIVERSAL DEFINITION OF MYOCARDIAL INFARCTION
Thygesen, K., Alpert, J., & White, H. (2008) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2008-4-5-91-105 · Cited by 525
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy
Schwartz, R. G., McKenzie, W. B., Alexander, J., Sager, P., D'Souza, A., Manatunga, A., Schwartz, P. E., Berger, H. J., Setaro, J., Surkin, L., et al. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90212-9 · Cited by 510
Burstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., Lehman, M., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
COBLEIGH, M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.013 · Cited by 488
Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy
Gottdiener, J. S. (1981) · Archives of Internal Medicine · doi:10.1001/archinte.141.6.758 · Cited by 486
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C., & Garratt, A. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122249299 · Cited by 473
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Redefining the Target: Chemotherapeutics as Antiangiogenics
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1195 · Cited by 395
Cardiac disturbances during the administration of taxol.
Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., & Donehower, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1704 · Cited by 395
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., & Ewer, M. S. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60896-3 · Cited by 388
Wu, S., Chen, J. J., Kudelka, A., Lu, J., & Zhu, X. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70003-2 · Cited by 386
Anthracycline associated cardiotoxicity in survivors of childhood cancer
Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008) · Heart · doi:10.1136/hrt.2007.136093 · Cited by 379
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Chen, M. H., Kerkelä, R., & Force, T. (2008) · Circulation · doi:10.1161/circulationaha.108.776831 · Cited by 379
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor
Goldberg, M., Antin, J., Guinan, E., & Rappeport, J. (1986) · Blood · doi:10.1182/blood.v68.5.1114.1114 · Cited by 371
Gupta, A., Lawrence, A. T., Krishnan, K., Kavinsky, C. J., & Trohman, R. G. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.01.040 · Cited by 362
Guarneri, V., Lenihan, D. J., Valero, V., Durand, J.-B., Broglio, K., Hess, K. R., Michaud, L. B., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Esteva, F. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9551 · Cited by 361
Trastuzumab‐associated cardiotoxicity
Keefe, D. L. (2002) · Cancer · doi:10.1002/cncr.10854 · Cited by 358
Rajkumar, S. V., Rosiñol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 343
Epidemiology of anthracycline cardiotoxicity in children and adults.
Ma, G., & Se, L. (1998) · PubMed · Cited by 341
Steinherz, L. J., Graham, T., Hurwitz, R., Sondheimer, H. M., Schwartz, R. G., Shaffer, E. M., Sandor, G., Benson, L., & Williams, R. (1992) · Pediatrics · doi:10.1542/peds.89.5.942 · Cited by 327
Mechanisms of Hypertension Associated With BAY 43-9006
Veronese, M. L., Mosenkis, A., Flaherty, K. T., Gallagher, M., Stevenson, J. P., Townsend, R. R., & O'Dwyer, P. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0503 · Cited by 324
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre, V. C., Shaikh, S. L., Mone, S. M., Gelber, R. D., & Colan, S. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.102 · Cited by 308
Silber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J., Hogarty, A. N., Cohen, M. I., Barber, G., Rutkowski, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.022 · Cited by 299
le Coutre, P., Ottmann, O. G., Giles, F., Kim, D.-W., Cortes, J., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O'Brien, S. G., et al. (2008) · Blood · doi:10.1182/blood-2007-04-083196 · Cited by 294
Sawyer, D. B., Zuppinger, C., Miller, T. A., Eppenberger, H. M., & Suter, T. M. (2002) · Circulation · doi:10.1161/01.cir.0000013839.41224.1c · Cited by 292
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
Tripathy, D., Slamon, D. J., Cobleigh, M., Arnold, A., Saleh, M., Mortimer, J. E., Murphy, M., & Stewart, S. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.557 · Cited by 280
Clinical Cardiac Tolerability of Trastuzumab
Perez, E. A., & Rodeheffer, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.120 · Cited by 280
Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor
Khakoo, A. Y., Kassiotis, C. M., Tannir, N., Plana, J. C., Halushka, M., Bickford, C., Trent, J., Champion, J. C., Durand, J., & Lenihan, D. J. (2008) · Cancer · doi:10.1002/cncr.23460 · Cited by 252
Self-citationCongestive heart failure is a rare event in patients receiving imatinib therapy
Atallah, E., Durand, J.-B., Kantarjian, H., & Cortes, J. (2007) · Blood · doi:10.1182/blood-2007-01-070144 · Cited by 252
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide
Westervelt, P., Brown, R. A., Adkins, D. R., Khoury, H., Curtin, P., Hurd, D., Luger, S. M., Ma, M. K., Ley, T. J., & DiPersio, J. F. (2001) · Blood · doi:10.1182/blood.v98.2.266 · Cited by 245
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine
Jensen, S. A., & Sørensen, J. B. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0178-1 · Cited by 232
Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies
Barbey, J. T., Pezzullo, J. C., & Soignet, S. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.009 · Cited by 230
Baz, R., Li, L., Kottke-Marchant, K., Srkalovic, G., McGowan, B., Yiannaki, E., Karam, M. A., Faiman, B., Jawde, R. A., Andresen, S., et al. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.12.1568 · Cited by 228
Management of thalidomide toxicity.
Ghobrial, I. M., & Rajkumar, S. V. (2003) · PubMed · Cited by 227
Oliveira, P. J., Bjork, J. A., Santos, M. S., Leino, R. L., Froberg, M. K., Moreno, A. J., & Wallace, K. B. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.005 · Cited by 227
Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F., Caccialanza, R., Invernizzi, R., Comotti, B., & Merlini, G. (2005) · Blood · doi:10.1182/blood-2004-08-3231 · Cited by 227
Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
Strevel, E. L., Ing, D. J., & Siu, L. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6925 · Cited by 211
Meinardi, M. T., van Veldhuisen, D. J., Gietema, J. A., Dolsma, W. V., Boomsma, F., van den Berg, M. P., Volkers, C., Haaksma, J., de Vries, E. G. E., Sleijfer, D. T., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2746 · Cited by 207
Chemotherapy-Induced Cardiotoxicity: Current Practice and Prospects of Prophylaxis
Gharib, M. I., & Burnett, A. K. (2002) · European Journal of Heart Failure · doi:10.1016/s1388-9842(01)00201-x · Cited by 200
A reassessment of cardiac toxicity associated with Taxol.
Arbuck, S. G., Strauss, W. H., Rowinsky, E. K., Christian, M. C., Suffness, M., Adams, J., Oakes, M., McGuire, W. P., Reed, E., & Gibbs, H. H. (1993) · PubMed · Cited by 195
Angiogenic growth factors and hypertension
Sane, D. C., Anton, L., & Brosnihan, K. B. (2004) · Angiogenesis · doi:10.1007/s10456-004-2699-3 · Cited by 195
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
Furuse, J., Ishii, H., Nakachi, K., Suzuki, E., Shimizu, S., & Nakajima, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00648.x · Cited by 194
Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.
Rezkalla, S., Kloner, R. A., Ensley, J., al-Sarraf, M., Revels, S., Olivenstein, A., Bhasin, S., Kerpel-Fronious, S., & Turi, Z. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.509 · Cited by 187
Chronic Health Conditions in Adult Survivors of Childhood Cancer
Oeffinger, K. C., Mertens, A. C., & Sklar, C. A. (2007) · Oncology Times · doi:10.1097/01.cot.0000265629.30194.8e · Cited by 187
Thalidomide and dexamethasone for resistant multiple myeloma
Anagnostopoulos, A., Weber, D., Rankin, K., Delasalle, K., & Alexanian, R. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04345.x · Cited by 177
Hypertension as a predictive factor of Sunitinib activity
Rixe, O., Billemont, B., & Izzedine, H. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm184 · Cited by 166
Symptomatic Cardiotoxicity Associated with 5‐Fluorouracil
Meyer, C. C., Calis, K. A., Burke, L. B., Walawander, C. A., & Grasela, T. H. (1997) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03748.x · Cited by 162
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic
Fernández, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., Wulf, S., Shavrin, A., Qin, C., Ma, J., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32373 · Cited by 158
5-Fluorouracil cardiotoxicity.
Lomeo, A. M., Avolio, C., Iacobellis, G., & Manzione, L. (1990) · PubMed · Cited by 157
Cavo, M., Zamagni, E., Cellini, C., Tosi, P., Cangini, D., Cini, M., Valdré, L., Palareti, G., Masini, L., Tura, S., et al. (2002) · Blood · doi:10.1182/blood-2002-06-1674 · Cited by 152
Review of Tests for Monitoring Doxorubicin-lnduced Cardiomyopathy
Ganz, W. I., Sridhar, K. S., Ganz, S. S., Gonzalez, R. R., Chakko, S. C., & Serafini, A. N. (2009) · Oncology · doi:10.1159/000227621 · Cited by 151
Cutsem, E. V., Hoff, P. M., Blum, J., Abt, M., & Osterwalder, B. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf108 · Cited by 149
Zonder, J. A., Barlogie, B., Durie, B. G. M., McCoy, J., Crowley, J. J., & Hussein, M. A. (2006) · Blood · doi:10.1182/blood-2006-01-0154 · Cited by 146
High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction
Quezado, Z., Wilson, W. H., Cunnion, R. E., Parker, M. M., Reda, D., Bryant, G., & Ognibene, F. P. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-1-199301010-00006 · Cited by 144
Anand, A. J. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800314 · Cited by 132
Voortman, J., & Giaccone, G. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-129 · Cited by 123
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes
Gianni, L., Salvatorelli, E., & Minotti, G. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0013-5 · Cited by 122
Ohnishi, K., Yoshida, H., Shigeno, K., Nakamura, S., Fujisawa, S., Naito, K., Shinjo, K., Fujita, Y., Matsui, H., Sahara, N., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402426 · Cited by 100
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Hatfield, A. K., Owen, S., & Pilot, P. R. (2007) · Nature Medicine · doi:10.1038/nm0107-13a · Cited by 100
Chemotherapy agents and hypertension: A focus on angiogenesis blockade
Jain, M. K., & Townsend, R. R. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0058-7 · Cited by 92
Bradycardia during therapy for multiple myeloma with thalidomide
Fahdi, I. E., Gaddam, V., Saucedo, J. F., Kishan, C. V., Vyas, K. S., Deneke, M. G., Razek, H. A., Thorn, B. T., Bissett, J. K., Anaisse, E., et al. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.12.061 · Cited by 91
Clark, T. E., Edom, N., Larson, J., & Lindsey, L. J. (2001) · Drug Safety · doi:10.2165/00002018-200124020-00002 · Cited by 87
Thromboembolic events with lenalidomide‐based therapy for multiple myeloma
Menon, S. P., Rajkumar, S. V., Lacy, M. Q., Falco, P., & Palumbo, A. (2008) · Cancer · doi:10.1002/cncr.23336 · Cited by 86
Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.
Pande, A. U., Lombardo, J. C., Spangenthal, E. J., et al. (2007) · PubMed · Cited by 85
Thalidomide in Cancer: Potential Uses and Limitations
Singhal, S., & Mehta, J. (2001) · BioDrugs · doi:10.2165/00063030-200115030-00003 · Cited by 81
The Diagnosis and Management of Cardiovascular Disease in Cancer Patients
Yusuf, S. W., Razeghi, P., & Yeh, E. T. H. (2008) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2008.01.002 · Cited by 80
Self-citationCardiac Toxicity of Trastuzumab-Related Regimens in HER2-Overexpressing Breast Cancer
Ewer, M. S., & O’Shaughnessy, J. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.017 · Cited by 78
Trastuzumab-Induced Cardiomyopathy
Guglin, M. E., Cutro, R. G., & Mishkin, J. D. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.02.002 · Cited by 76
Thalidomide Therapy and Deep Venous Thrombosis in Multiple Myeloma
Rajkumar, S. V. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.12.1549 · Cited by 71
Thrombosis in multiple myeloma
Zangari, M., Elice, F., Fink, L. M., & Tricot, G. J. K. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.3.307 · Cited by 68
Angiotensin-Converting Enzyme Inhibitors for Bevacizumab-Induced Hypertension
Dinçer, M., & Altundağ, K. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h244 · Cited by 68
Coronary spasm induced by capecitabine
Schnetzler, B., Popova, N., Lamb, C. C., & Sappino, A. P. (2001) · Annals of Oncology · doi:10.1023/a:1011152931300 · Cited by 60
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Rosti, G., Martinelli, G., & Baccarani, M. (2007) · Nature Medicine · doi:10.1038/nm0107-15a · Cited by 59
Risk of Thrombosis With Lenalidomide and Its Prevention With Aspirin
Hirsh, J. (2007) · CHEST Journal · doi:10.1378/chest.06-2360 · Cited by 58
Thalidomide-Induced Sinus Bradycardia
Kaur, A., Yu, S. S., Lee, A. J., & Chiao, T. B. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d003 · Cited by 56
Sorafenib for Metastatic Renal Cancer
Riechelmann, R. P., Chin, S. F., Wang, L. E., Tannock, I. F., Berthold, D., Moore, M. J., & Knox, J. J. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181574084 · Cited by 52
Schütt, P., Ebeling, P. R., Buttkereit, U., Brandhorst, D., Opalka, B., Poser, M., Müller, S., Flaßhove, M., Moritz, T., Seeber, S., et al. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1007-7 · Cited by 33
What is QT interval prolongation?
Vorchheimer, D. A. (2005) · PubMed · Cited by 12
Ray, A., Ray, S., & Koner, B. C. (2004) · TSpace (University of Toronto) · Cited by 6
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Metadata
- Authors
- Yeh, E. T. H., & Bickford, C. L.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 53
- Issue
- 24
- Pages
- 2231-2247
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2769648988
- Cited by
- 1,275
- References
- 148
- FWCI
- 31.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.